Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | TSHR | P16473 | 2/20 | 0.34 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.34 |
| ▸ | PDPK1 | O15530 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.33 |
| ▸ | TRPV1 | Q8NER1 | 5/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5359887 | 0.73 | TP53 (0.36) | PTGS1MAPTALDH1A1TSHRKDM4E | |
| SCHEMBL5361990 | 0.69 | CYP11B1 (0.37) | MAPTTSHRPTGS2CYP2C9 | |
| SCHEMBL5367157 | 0.67 | ALDH1A1 (0.34) | MAPTALDH1A1TSHRKDM4EPOLB | |
| SCHEMBL12361462 | 0.66 | PTGS1 (0.58) | PTGS1ALDH1A1PTGS2PDPK1KDM4E | |
| SCHEMBL12871652 | 0.66 | PTGS1 (0.58) | PTGS1MAPTALDH1A1PTGS2PDPK1 | |
| SCHEMBL14641147 | 0.65 | MAPT (0.47) | PTGS1MAPTALDH1A1TSHRPTGS2 | |
| SCHEMBL28051010 | 0.64 | ALDH1A1 (0.41) | PTGS1MAPTALDH1A1TSHRPTGS2 | |
| SCHEMBL3148117 | 0.64 | P2RX7 (0.37) | PTGS2 | |
| SCHEMBL12361491 | 0.63 | PTGS1 (0.54) | PTGS1PTGS2PDPK1KLKB1TRPV1 | |
| SCHEMBL12361494 | 0.63 | PTGS1 (0.54) | PTGS1ALDH1A1PTGS2KDM4EKLKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090270361-A1 | Substituted pyrazole derivatives and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-10-29 | — | — | US | disclosed |
| WO-2009119880-A1 | SUBSTITUTED PYRAZOLE DERIVATIVES AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-10-01 | — | — | WO | disclosed |
| WO-2007145349-A2 | SUBSTITUTED PYRROLE DERIVATIVES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270361-A1 | Substituted pyrazole derivatives and use thereof | CBR3, CBR1, NOX5 | PTGS1 1840/4885MAPT 3590/4885ALDH1A1 1105/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.